Stock analysts at StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO – Get Rating) in a research note issued to investors on Monday. The firm set a “strong-buy” rating on the medical research company’s stock.
Global Cord Blood Stock Performance
Shares of Global Cord Blood stock opened at $2.99 on Monday. The firm has a fifty day moving average of $2.99 and a two-hundred day moving average of $2.99. Global Cord Blood has a one year low of $2.03 and a one year high of $5.50.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Clark Financial Services Group Inc. BD acquired a new stake in Global Cord Blood during the first quarter worth approximately $37,000. Northern Trust Corp purchased a new stake in shares of Global Cord Blood in the second quarter valued at $96,000. Natixis Advisors L.P. increased its stake in Global Cord Blood by 6.6% in the first quarter. Natixis Advisors L.P. now owns 189,330 shares of the medical research company’s stock valued at $729,000 after purchasing an additional 11,709 shares during the last quarter. Finally, Moneta Group Investment Advisors LLC lifted its position in Global Cord Blood by 99,844.5% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 26,093,520 shares of the medical research company’s stock worth $77,957,000 after buying an additional 26,067,412 shares during the period.
About Global Cord Blood
Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.
Featured Stories
- Get a free copy of the StockNews.com research report on Global Cord Blood (CO)
- MarketBeat Week in Review – 5/29 – 6/2
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
- Constellation Brands Taps into Growth: Analysts Bullish on Stock
- CrowdStrike: Another Tech Stock to Buy on the Dip
Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.
